- Enrollment is on track in the ongoing Phase 1/2 clinical trial of QR-110 with eight out of twelve patients with LCA 10 enrolled.
- The trial is on track to announce interim six-month data on safety, effects on vision and retinal structure in the second half of the year.
- ProQR to present two abstracts on programs for Fuchs endothelial corneal dystrophy and Stargardt’s disease at the ARVO annual meeting. The company will also deliver a presentation during the Foundation Fighting Blindness/Casey Innovation summit prior to ARVO.
“We are very pleased with the enrollment in our trial and the continued enthusiasm from our investigators in helping bring a novel and first-in-class treatment to LCA 10 patients that have no other treatment options,” said
Presentations at ARVO conference
ProQR will present data from two ophthalmology programs at the 2018 annual meeting of the
|Oral Presentation:||RNA toxicity induced by TCF4 CTG expansions is ameliorated by antisense therapeutics in a patient-derived cell model of Fuchs corneal endothelial dystrophy (FECD)|
|Presenter:||Dr. Alice Davidson of UCL Institute of Ophthalmology, London|
|Date:||Tuesday, May 1|
|Time:||12:45 - 1:00pm HAST|
|Poster Presentation:||Oligonucleotide-based splice correction of the ABCA4 c.5461-10T>C mutation in Stargardt’s disease type 1|
|Presenter:||Kalyan Dulla, Ph.D., director of non-clinical research of ProQR|
|Poster #:||5315 - C0248|
|Date:||Wednesday, May 2|
|Time:||3:30 – 5:15pm HAST|
|Oral Presentation:||Retinal organoids from IRDs resulting from intronic mutations provide powerful models to both validate pharmacological treatment approaches and determine initial dose-ranging in clinical studies|
|Presenter:||Dr. Peter Adamson, Senior Vice President, Ophthalmology Franchise of ProQR|
|Session:||FFB/Casey Innovation summit prior to ARVO: Retinal Cell and Gene Therapy|
|Date:||Friday, April 27|
|Time:||10:45 – 11:00am HAST|
About the PQ-110-001 trial
PQ-110-001 is an open-label trial that has been designed to enroll approximately six children (age 6 - 17 years) and six adults (≥ 18 years) who have LCA 10 due to one or two copies of the p.Cys998X mutation in the CEP290 gene. Patients are receiving four intravitreal injections of QR-110 into one eye; one every three months. The trial is being conducted at three specialized centers with significant expertise in genetic retinal disease: the
The primary objectives of the trial are safety and tolerability. Secondary objectives include pharmacokinetics as well as restoration/improvement of visual function and retinal structure through ophthalmic endpoints such as visual acuity, full field stimulus testing (FST), optical coherence tomography (OCT), pupillary light reflex (PLR), mobility course and fixation stability. Changes in quality of life in the trial subjects are also being evaluated.
About Leber’s Congenital Amaurosis 10
Leber’s congenital amaurosis (LCA) is the most common cause of blindness due to genetic disease in children and consists of a group of diseases of which LCA 10 is one of the more severe forms. LCA 10 is caused by mutations in the CEP290 gene, of which the p.Cys998X mutation is the most common. LCA 10 leads to early loss of vision causing most people to lose their sight in the first few years of life. To date, there are no treatments approved or other products in clinical development that treat the underlying cause of the disease. Approximately 2,000 people in the Western world have LCA 10 because of this mutation.
QR-110 is a potential first-in-class investigational RNA-based oligonucleotide designed to address the underlying cause of Leber’s congenital amaurosis 10 due to the p.Cys998X mutation in the CEP290 gene. The p.Cys998X mutation is a substitution of one nucleotide in the pre-mRNA that leads to aberrant splicing of the mRNA and non-functional CEP290 mRNA. QR-110 is designed to restore normal (wild-type) CEP290 mRNA leading to the production of normal CEP290 protein by binding to the mutated location in the pre-mRNA causing normal splicing of the pre-mRNA. QR-110 is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in
About Fuchs Endothelial Corneal Dystrophy
Fuchs endothelial corneal dystrophy (FECD) is a common inherited condition characterized by the dysfunction and degeneration of the corneal endothelium, a single cell layer of cells on the inside of the cornea. There are different types of this disease and we focus on age-related FECD (FECD3). Some patients with age-related FECD develop advanced disease with corneal edema and corneal clouding. These symptoms can lead to complete vision loss and the need for surgery and a corneal transplant.
QRX-504 is a potential first-in-class investigational RNA-based oligonucleotide designed to prevent corneal dystrophy in patients that have FECD3 due to trinucleotide repeat expansions in the TCF4 gene. QRX-504 binds to the mutated TCF4 mRNA and thereby stops the formation of toxic aggregates that cause the disease. QRX-504 is intended to be administered through intraocular injection into the eye.
About Stargardt’s Disease
Stargardt’s disease (fundus flavimaculatus) is a form of juvenile macular degeneration which causes progressive central vision loss, reduced visual acuity, impaired color vision and problems in night vision. The signs and symptoms typically appear in late childhood to early adulthood and worsen over time with loss of peripheral vision.
QRX-1011 is a potential first-in-class investigational RNA-based oligonucleotide that aims to treat vision loss caused by the specific c.5461-10T>C mutation in ABCA4 gene which leads to an important part of the protein being deleted. QRX-1011 modulates splicing of the mRNA and leads to inclusion of the deleted sequence and formation of functional, wild-type ABCA4 protein which will potentially stop and perhaps reverse the progression of the disease.
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding QR-110 and the clinical development and the therapeutic potential thereof, statements regarding PQ-110-001, including trial design and expected timing of results, statements regarding orphan drug designation, and statements regarding our ongoing and planned discovery and development of product candidates and the timing thereof, including those in our innovation pipeline, including without limitation QRX-504 and QRX-1011. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, including that positive results observed in our prior and ongoing studies may not be replicated in later trials or guarantee approval of any product candidate by regulatory authorities, that we may not realize any intended benefits of orphan drug designation, manufacturing processes and facilities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors in our filings made with the
Chief Financial Officer
T: +1 415 231 6431
Source: ProQR Therapeutics N.V.